Truist Financial Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price objective cut by research analysts at Truist Financial from $100.00 to $43.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 157.33% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Wedbush restated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Bank of America lowered their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Finally, Scotiabank cut their price objective on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Keros Therapeutics Stock Down 2.4 %

KROS opened at $16.71 on Monday. The firm has a market cap of $676.87 million, a price-to-earnings ratio of -3.21 and a beta of 1.20. Keros Therapeutics has a 52 week low of $15.67 and a 52 week high of $73.00. The business’s 50 day moving average is $54.10 and its two-hundred day moving average is $51.40.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same period last year, the business posted ($1.33) EPS. Keros Therapeutics’s revenue was up 4750.0% compared to the same quarter last year. Equities analysts expect that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KROS. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. KBC Group NV boosted its position in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its position in Keros Therapeutics by 36.7% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock worth $223,000 after purchasing an additional 1,033 shares in the last quarter. Arizona State Retirement System grew its holdings in Keros Therapeutics by 16.3% in the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after purchasing an additional 1,130 shares during the last quarter. Finally, Algert Global LLC increased its position in shares of Keros Therapeutics by 10.6% in the second quarter. Algert Global LLC now owns 15,700 shares of the company’s stock valued at $717,000 after buying an additional 1,505 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.